



## **Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares**

February 7, 2023

SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the closing of its previously announced upsized initial public offering of 12,351,000 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,611,000 additional ADSs, at a public offering price of \$15.00 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering were approximately \$185.3 million before deducting underwriting discounts and commissions and offering expenses. All of the ADSs were offered by Structure Therapeutics. The shares began trading on the Nasdaq Global Market on February 3, 2023 under the ticker symbol "GPCR."

Jefferies, SVB Securities, Guggenheim Securities, and BMO Capital Markets acted as joint book-running managers for the offering.

Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on February 2, 2023. The offering was made only by means of a written prospectus. A copy of the final prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, telephone: (877) 821-7388, email: Prospectus\_Department@Jefferies.com; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, email: syndicate@svbsecurities.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@guggenheimpartners.com; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 W 42<sup>nd</sup> Street, 32<sup>nd</sup> Floor New York, NY 10036, telephone: (800) 414-3627, email: bmoprospectus@bmo.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### **About Structure Therapeutics**

Structure Therapeutics is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. By leveraging its next generation structure-based drug discovery platform, the company has built a pipeline including two clinical-stage small molecule compounds designed to overcome the limitations of biologics and peptide therapies. The company is currently focused on the GPCR family of drug targets.

### **Contacts:**

#### **Investor Relations:**

Jun Yoon, Chief Financial Officer  
Structure Therapeutics Inc.  
ir@structuretx.com